BriaCell Therapeutics’ (BCTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of BriaCell Therapeutics (NASDAQ:BCTX) in a report issued on Thursday,Benzinga reports. They currently have a $15.00 target price on the stock.

BriaCell Therapeutics Trading Down 0.2 %

BCTX opened at $0.66 on Thursday. The firm’s 50 day moving average is $0.84 and its 200-day moving average is $0.89. BriaCell Therapeutics has a 52-week low of $0.46 and a 52-week high of $5.97.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.45. On average, sell-side analysts anticipate that BriaCell Therapeutics will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned approximately 0.44% of BriaCell Therapeutics as of its most recent SEC filing. 15.42% of the stock is owned by institutional investors and hedge funds.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.